Article Details

Starpharma's DEP® Irinotecan Outperforms Other leading Cancer Drugs

Retrieved on: 2019-05-23 22:02:25

Tags for this article:

Click the tags to see associated articles and topics

Starpharma's DEP® Irinotecan Outperforms Other leading Cancer Drugs. View article details on hiswai:

Excerpt

<div>To conduct the study, the xenograft study used an HT-29 cell line. ... to $9.5 in 2017, according to <b>Arcview Market Research</b> and BDS Analytics.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up